PVG urges Anavex stockholders to vote the GOLD proxy card FOR all six PVG nominees and support meaningful change, stronger alignment and a focused plan to restore and maximize shareholder value.
The campaign’s case for change is built around three core priorities: stronger shareholder alignment, a Board with the right experience for Anavex’s next phase and a focused plan to restore and maximize shareholder value.
Anavex needs a Board that is meaningfully aligned with the stockholders it represents. PVG’s campaign emphasizes ownership, accountability and a Board willing to actively oversee management and capital allocation.
See the choice →PVG’s six nominees bring complementary experience across biotechnology investing, pharmaceutical leadership, healthcare investment banking, neuroscience, public-company leadership, capital markets and asset management.
Compare the six pairings →PVG’s presentation sets out priorities to strengthen leadership, advance blarcamesine, unlock pipeline value and improve long-term shareholder alignment.
See PVG’s plan →Review the campaign’s case for change, compare the nominees and vote the GOLD proxy card FOR the six PVG nominees.
Current ANVX Board
Your vote is important, no matter how many shares you own. Follow the instructions provided with your GOLD proxy materials and submit your vote as soon as possible.
Visit the voting website printed on your GOLD proxy card and enter your unique control number.
Call the telephone number printed on your GOLD proxy card and follow the automated instructions using your control number.
Mark, sign and date your GOLD proxy card and return it promptly in the enclosed postage-paid envelope.
PVG’s shareholder presentation compares each nominee directly with the corresponding member of the Current ANVX Board slate. Review the campaign’s stated differences in experience, ownership and alignment.
PVG candidate Patrick Adams brings 40+ years in biotech investing and capital allocation experience, has been successful in investing in the biotechnology sector, has vast experience with CNS companies, and was an investor in Axsome and many other CNS companies.
Current Board Chair Jiong Ma has an SPAC background (presiding over Mobix Labs’ 90% loss in shareholder value), zero biopharma experience, and owns 0 shares of AVXL.
Long-term biotechnology investing and capital-allocation experience, contrasted with concerns about SPAC experience, biopharma expertise and shareholder alignment.
PVG candidate Rene Mora not only holds a physician's background (M.D., Ph.D.), but also boasts two decades of healthcare investment banking at Leerink and five years managing a healthcare portfolio at Monashee.
Peter Donhauser’s background as a physician lacks the operational and financial technicality that are necessary in running a successful biotech company.
Healthcare investment banking and portfolio-management experience, contrasted with concerns about the opposing candidate’s operating and financial background.
PVG candidate John Boris brings a 41-year financial and executive career built entirely inside the pharmaceutical industry. John worked for Eli Lilly from 1985 to 1989, ending his tenure as Head of New Product and Sales, leading the Prozac team and Warner-Lambert from 1990 to 1997 (acquired by Pfizer) as Senior Manager, Neurosciences.
Van der Velden has chaired AVXL’s Audit Committee through delinquent quarterly filings and has a Telecom background.
Deep pharmaceutical-industry experience, contrasted with concerns about the opposing candidate’s sector background and audit-committee record.
PVG candidate Curtis Hogue has served as both Interim CEO and director of a publicly traded biopharma company; serving as an Interim CEO and director of Alaunos Therapeutics from 2023-2025, and a Rett syndrome charity, as well as 20+ years of experience in biotech equities.
Axel Paeger’s executive record is in hospital group operations, not drug development; he holds no shares or options at AVXL, having no skin-in-the-game either.
Public-biopharma leadership and biotech-equities experience, contrasted with concerns about hospital-operations experience and shareholder alignment.
PVG candidate Jason Kolbert has spent 25+ years covering biotechnology and neuroscience specifically, working for such firms as Salomon Smith Barney (Citibank) and Maxim Group, and has analyzed the clinical development strategies and regulatory hurdles Blarcamesine now requires. He also worked for NeoStem Pharmaceuticals as Chief Business Officer from 2010-2012.
Adrian Senderowicz’s development and regulatory experience was built in oncology, which is a regulatory pathway that bears little to no resemblance to neurodegeneration.
Biotechnology and neuroscience experience, contrasted with concerns about oncology-focused development and regulatory experience for a neurodegeneration-focused company.
PVG candidate Ralf von Ziegesar has spent 30+ years in asset management and serves as Managing Director of FOCAM AG; he is familiar with the importance of long-term investing.
While Gautam Patel brings healthcare credentials, he has no background experience in CNS or neurodegeneration specific companies, and would be expected to oversee a Phase 3 trial.
Long-term asset-management experience, contrasted with concerns about CNS and neurodegeneration-specific experience.
The presentation organizes the campaign's forward plan around leadership, blarcamesine, pipeline value and shareholder alignment.
Recruit experienced CNS or rare-disease leadership and rebuild management and clinical capabilities.
Establish a credible regulatory pathway and strengthen execution toward approval and commercialization.
Explore strategic partnerships, protect intellectual property and prioritize value across additional programs.
Build an active board with meaningful ownership expectations and stronger accountability to shareholders.
Vote FOR the six PVG nominees.
Vote GOLD →Copyright 2022 | All Rights Reserved | Sitemap | Website by Plumb Development a Digital Marketing Agency